Fact CheckerSign in

NCT03343236Active, not recruiting

Nutrition and Inflammation in Patients With Head and Neck Cancer

Inflammation and Metabolism After Radiotherapy- Predictors of Survival in Patients With Head and Neck Cancer

Source: ClinicalTrials.gov · Last updated 13 Dec 2024

Brief summary (registry, in English)

An estimated 1500 people in Sweden will annually be diagnosed with head and neck cancer (HNC). Five year survival is approximately 69%. Long-term sequelae are common and in particular nutritional problems and fatigue. Radiotherapy (RT) is the cornerstone of treatment, either as single modality treatment or combined modality treatment. RT can induce immune responses at the site of tumor. It has been demonstrated that RT can lead to a strong systemic immune response . We have previously shown that an increase of conventional measures of systemic immune response to RT varied significantly across individuals. We predict that local immune response plays a major role in the antitumor effect. We also predict that a strong systemic immune response contributes to malnutrition and influence on survival. And malnutrition may lead to a worse response to RT. The overall aim of this multicenter observational longitudinal study is to prospectively identify immunological and metabolic variables that affect the outcome of HNC patients. We will systematically investigate the local and systemic immune response induced by RT as well as explore alterations in metabolite composition induced by disease and treatment through global metabolite profiling. A platform for studies on immuno-metabolic changes in HNC patients has been established in the Uppsala-Orebro and Northern regions. Approximately 370 patients per year are eligible. Findings in this study can have implications on the development of personalized therapy in patients with HNC. The long-term benefit of the study will be the identification of measures for improved patient surveillance in order to improve the general and nutritional outcomes.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
522 (actual)
First submitted
10 Nov 2017
Start date
1 Nov 2015
Primary completion date
31 Dec 2025
Lead sponsor
Uppsala University
NCT number
NCT03343236

What you commit to

  • Study type: Observational
  • Participants enrolled: 522
  • From 1 Nov 2015 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous treatment for malignant disease except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish

Who the study is looking for

  • Patients with newly diagnosed head and neck cancer

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Otolaryngology, Head & Neck Surgery, Uppsala University Hospital
Coordinator of this site? Confirm its status
UppsalaSwedenUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.